In a cohort of patients bearing EGFR mutant lung cancers, increased peripheral natural killer cells and INFγ were observed after 4 weeks of gefitinib treatment while circulating IL6 levels were decreased, especially in those patients sensitive to gefitinib [78]. Here, EGFR is linked to lung cancer.